Simone Breiteneicher
Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study
Beigel F, Brand S, Göke B, Rust C, Breiteneicher S, Maul J, Lammert F, Howaldt S, Teich N, Ochsenkühn T. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. J Crohns Colitis 2014; 8:1471-9.
Jun 19, 2014Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study
Jun 19, 2014J Crohns Colitis 2014; 8:1471-9
Beigel Florian, Brand Stephan, Göke Burkhard, Rust Christian, Breiteneicher Simone, Maul Jochen, Lammert Frank, Howaldt Stefanie, Teich Niels, Ochsenkühn Thomas
Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies
Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PloS one 2014; 9:e99293.
Jun 16, 2014Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies
Jun 16, 2014PloS one 2014; 9:e99293
Beigel Florian, Deml Matthias, Schnitzler Fabian, Breiteneicher Simone, Göke Burkhard, Ochsenkühn Thomas, Brand Stephan
Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies
Beigel F, Brand S, Seiderer J, Göke B, Laubender R, Van Steen K, John J, Breiteneicher S, Tillack C, Schnitzler F, Steinborn A, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014; 23:735-44.
Apr 30, 2014Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies
Apr 30, 2014Pharmacoepidemiol Drug Saf 2014; 23:735-44
Beigel Florian, Brand Stephan, Seiderer Julia, Göke Burkhard, Laubender Rüdiger P, Van Steen Kristel, John Jestinah Mahachie, Breiteneicher Simone, Tillack Cornelia, Schnitzler Fabian, Steinborn Anni, Ochsenkühn Thomas
Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease
Beigel F, Ochsenkühn T, Seiderer J, Göke B, Weidinger M, Breiteneicher S, Schnitzler F, Tillack C, Laubender R, Löhr B, Brand S. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion 2011; 85:47-54.
Dec 14, 2011Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease
Dec 14, 2011Digestion 2011; 85:47-54
Beigel Florian, Ochsenkühn Thomas, Seiderer Julia, Göke Burkhard, Weidinger Maria, Breiteneicher Simone, Schnitzler Fabian, Tillack Cornelia, Laubender Rüdiger P, Löhr Beate, Brand Stephan